The most recent revision of the American Heart As sociation guidelines on infective endocarditis pro phylaxis occurred in 2007. These revisions were based on the fact that current data have brought in to question the benefit of previous recommenda tions for infective endocarditis prophylaxis. It was noted that the bacteremia that occurs following dental procedures represents only a fraction of the episodes of bacteremia that occur with activities of daily living (such as chewing, brushing teeth and other oral hygiene measures). The target groups and the procedures for which prophylaxis is reason able have been significantly reduced in number. The focus is now on patients who are most likely to have adverse outcomes from infectious endocardi tis. The present article is targeted at practicing Canadian physicians and provides the rationale for the current recommendations. In addition to a sum mary of the indications for prophylaxis, information is provided on the conditions for which prophylaxis is not recommended.
In 2007, the American Heart Association (AHA) and the British Society for Antimicrobial Chemotherapy un dertook major revisions of their infective endocarditis (IE) prophylaxis guidelines. These revisions were aimed at simplifying recommendations and ensuring consistency with the published evidence over the past two decades [1] [2] . The target groups and the proce dures for which prophylaxis is reasonable have been drastically reduced in number. The current article is a synopsis of the AHA Committee's recommendations, along with a provision of the rationale for the recom mendations. The full guidelines are available at http:// circ.ahajournals.org and were endorsed by the Infec tious Diseases Society of America, the Pediatric Infec tious Diseases Society and the Council on Scientific Affairs of the American Dental Association.
Primary reasons for revision of the AHA guidelienes
The new guidelines were not based on the results of a single study but rather on the collective body of evi dence published in numerous studies over the past two decades. The Committee sought to construct the present guidelines such that they would be in the best interest of patients and providers, would be reasonable and prudent, and would represent the conclusions of published studies and the collective wisdom of many experts on IE and relevant national and international societies. Four primary reasons were cited to form the rationale for revising the guidelines:
• IE is much more likely to result from frequent expo sure to random bacteremias associated with daily activities than from bacteremia caused by a dental, gastrointestinal (GI) tract or genitourinary (GU) tract procedure.
• Prophylaxis prevents an exceedingly small number of cases of IE, if any, in individuals who undergo a dental, GI tract or GU tract procedure.
• The risk of antibiotic-associated adverse events ex ceeds the benefit, if any, from prophylactic antibiot ic therapy except in very high-risk situations.
• Maintenance of optimal oral health and hygiene may reduce the incidence of bacteremia from daily activities and thus the risk of IE, and is more impor tant than the use of prophylactic antibiotics for den tal procedures.
Target groups for prophylaxis
The new guidelines suggest that prophylaxis should be targeted at conditions that are associated with the highest probability of adverse outcomes from IE. For example, it has been determined that the risk of mor tality from IE due to viridans streptococcal infection of prosthetic valves is at least 20% [3] - [5] , while the mortali ty in the case of native valves is 5% or less [6] - [8] . In this regard, prophylaxis is reasonable for patients with the following conditions ( Table 1 ):
• Prosthetic cardiac valve or prosthetic material used for valve repair
• Previous IE
• Congenital heart disease (CHD) -Unrepaired cyanotic CHD, including palliative shunts and conduits -Completely repaired congenital heart defect with prosthetic material or device, whether placed by surgery or by catheter intervention, during the first six months after the procedure -Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device (which inhibit endothelializa tion)
• Cardiac transplant recipients who develop cardiac valvulopathy 
Prophylaxis indicated Prophylaxis not indicated

Prosthetic cardiac valves Previous infective endocarditis
Unrepaired cyanotic congenital heart disease, in cluding palliative shunts and conduits
Completely repaired congenital heart defect with prosthetic material or device, during the first six months after the procedure Repaired congenital heart disease with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device (which in hibit endothelialization) It should be noted that with the exception of the condi tions listed above, antibiotic prophylaxis is no longer recommended for any other form of CHD. With respect to prosthetic material, prophylaxis is reasonable for six months because endothelialization of prosthetic mater ial usually occurs within six months after valve place ment.
In the new guidelines, the Committee noted that mitral valve prolapse (MVP) is the most common underlying condition that predisposes to the acquisition of IE in the western world, but the absolute incidence of IE is extremely low in this population. In addition, IE with MVP is not usually associated with the grave out comes associated with the conditions noted above. Consequently, IE prophylaxis is no longer recommend ed for patients with MVP.
The new guidelines did not specifically address the is sue of rheumatic heart disease. However, in some centres, patients with significant residual valvular dis ease due to rheumatic heart disease continue to be re garded as candidates for prophylaxis [9] . This notwith standing, current AHA recommendations no longer routinely suggest prophylaxis for patients with rheumatic heart disease [10] .
Dental procedures for which endocarditis prophylaxis is reasonable for patients in the high-risk target group
In addition to identifying the underlying cardiac condi tions that warrant prophylaxis, the Committee ad dressed the dental procedures for which prophylaxis is warranted if such procedures are performed in highrisk patients. The duration of bacteremia following sev eral activities of daily living, such as chewing food and tooth brushing, far exceed that due to a single tooth extraction, for example [11] [12] . For illustrative purposes, these durations have been estimated to be 5730 min over a one-month period for the activities of daily living [11] , compared with 6 min to 30 min for a single tooth extraction [12] . The procedures for which prophylaxis is reasonable are as follows:
• All dental procedures that involve the manipulation of gingival tissue, the periapical region of teeth or the perforation of the oral mucosa.
The following procedures and events do not require prophylaxis:
• Routine anesthetic injections through noninfected tissue, taking dental radiographs, placement of re movable prosthodontic or orthodontic appliances, adjustment of orthodontic appliances, placement of orthodontic brackets, shedding of deciduous teeth, and bleeding from trauma to the lips or oral mu cosa.
Antibiotic regimens for dental and other procedures
Antibiotics for prophylaxis should be administered in a single dose before the procedure. If the antibiotic is in advertently not given before the procedure, it may be administered up to 2 h after the procedure. It should be noted that rarely, some patients who are scheduled for an invasive procedure may have a coincidental IE. The presence of fever or other manifestations of systemic infection should alert the provider to the possibility of IE, and it is important to obtain blood cultures and oth er relevant tests before administration of antibiotics in tended to prevent IE. This is important in preventing a delay in the diagnosis or treatment of a concomitant case of IE. Table 2 summarizes the recommended antibiotic regi mens for dental procedures. Amoxicillin is the pre ferred choice for oral therapy because it is well ab sorbed from the GI tract and provides high and sus tained serum concentrations. For individuals who are allergic to penicillin or amoxicillin, the use of cephalex in or another first-generation oral cephalosporin, clin damycin, azithromycin or clarithromycin is recom mended. Cephalosporins should not be administered to patients with a history of penicillin hypersensitivity reactions that resulted in systemic anaphylaxis, an gioedema or urticaria. Patients who are unable to toler ate an oral antibiotic may be treated with parenteral ampicillin, ceftriaxone or cefazolin. Ampicillin-allergic patients who are unable to tolerate an oral agent may be treated with parenteral cefazolin, ceftriaxone or clin damycin (avoiding the cephalosporins if there is a his tory of anaphylaxis, angioedema or urticaria).
Dental procedures
Respiratory tract procedures
Patients who require prophylaxis may be given the regimens in Table 2 . This applies to individuals who undergo an invasive procedure of the respiratory tract that involves incision or biopsy of the respiratory mu cosa, such as tonsillectomy and adenoidectomy. Pro phylaxis is not required for bronchoscopy unless the procedure involves incision of the respiratory tract mu cosa. If a patient is undergoing a procedure for an es tablished respiratory tract infection, the regimen should include antibiotics that are effective against the likely pathogens in addition to viridans streptococci. For ex ample, antistaphylococcal agents should be used if in fection is known or suspected to be caused by Staphy lococcus aureus.
GI or GU tract procedures
Prophylaxis is no longer recommended for these pa tients. However, for high-risk patients who have an es tablished GI or GU tract infection, or for those who re ceive antibiotic therapy to prevent wound infection or sepsis associated with a GI or GU tract procedure, the antibiotic regimen should include an agent active against enterococci, such as ampicillin or vancomycin.
For high-risk patients who are scheduled for an elec tive cystoscopy or other urinary tract manipulation and who have an enterococcal urinary tract infection or col onization, antibiotic therapy to eradicate enterococci from the urine before the procedure may be consid ered. If the urinary tract procedure is not elective, it may be reasonable to include an agent active against enterococci in the empiric or specific perioperative an timicrobial regimen administered to the patient. 
Summary
The 2007 AHA guidelines are significantly different from previous guidelines, with significantly fewer pa tients being targeted for prophylaxis. Clinicians should become familiar with these guidelines -a synopsis of the guidelines is provided in the present document. The AHA Committee recognizes the need for more da ta to guide future changes to the IE prophylaxis guide lines. Prospectively designed clinical studies are en couraged. Given the low incidence of IE, such studies would need to be multicentred and would take several years to complete.
